North Star Asset Management Inc. Makes New $33.12 Million Investment in Stryker Corporation $SYK

North Star Asset Management Inc. purchased a new stake in Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 105,188 shares of the medical technology company’s stock, valued at approximately $33,118,000. Stryker accounts for 1.3% of North Star Asset Management Inc.’s investment portfolio, making the stock its 20th biggest position.

A number of other institutional investors also recently modified their holdings of SYK. Varma Mutual Pension Insurance Co increased its holdings in shares of Stryker by 10.5% during the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock worth $18,842,000 after buying an additional 5,100 shares in the last quarter. QRG Capital Management Inc. boosted its holdings in shares of Stryker by 7.4% during the 4th quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock valued at $21,281,000 after acquiring an additional 4,186 shares in the last quarter. Swedbank AB grew its position in Stryker by 6.6% during the 4th quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock worth $45,349,000 after acquiring an additional 7,934 shares during the last quarter. Crossmark Global Holdings Inc. grew its position in Stryker by 31.1% during the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock worth $9,426,000 after acquiring an additional 6,367 shares during the last quarter. Finally, Royal Bank of Canada increased its holdings in Stryker by 6.5% in the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after purchasing an additional 199,863 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Price Performance

Stryker stock opened at $322.20 on Friday. The stock has a market capitalization of $123.58 billion, a price-to-earnings ratio of 33.39, a PEG ratio of 2.10 and a beta of 0.76. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock’s 50 day moving average price is $328.64 and its two-hundred day moving average price is $331.47.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same period in the previous year, the firm posted $3.13 earnings per share. The business’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities analysts predict that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio is presently 36.48%.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 300,000 shares of Stryker stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the completion of the transaction, the director directly owned 2,301,375 shares in the company, valued at $773,031,862.50. This trade represents a 11.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Dylan Bram Crotty sold 441 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider directly owned 6,102 shares of the company’s stock, valued at $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 351,267 shares of company stock valued at $118,197,701. Corporate insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on SYK shares. UBS Group assumed coverage on shares of Stryker in a report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price objective for the company. The Goldman Sachs Group reissued a “neutral” rating and set a $361.00 target price on shares of Stryker in a report on Friday, May 1st. Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stryker in a research note on Friday, July 31st. Finally, Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.